Background: Preoperative anxiety (an unpleasant tension brought on by a patient’s anxiety about hospitalisation, anaesthesia, and surgery) is exacerbated by the fact that cancers are life-threatening and by the related fear of recurrence or death.Therefore, this study aimed to evaluate the impact of preoperative oral melatonin on anxiolysis, sedation, sleepiness, and hemodynamic response to intubation, as compared to a placebo control group. Materials &Methods: The study was carried out on 60 cancer patients between the ages of 18 and 60 who had ASA physical status Grades 1 and 2 and receiving elective oncological procedures under general anesthesia. The patients were randomly assigned into two groups (Group-C and Group-M) by computer generated random number.Ramsay sedation score, Stanford sleepiness scale, Haemodynamic parameters such as HR, SBP, DBP and MAP were recorded. Results: The mean age in group M was 39.9 years and in C group was 45.1 years. There were 21 males and 9 females and 24 males and 6 females. The height was 157.1 cm and 155.8 cm, weight was 53.7 cm and 55.3 cm, HR variability was 83.3 beats/min and 82.2 beats/min, SBP was 118.8 and 116, DBP was 82.4 mm Hg and 84.6 mm Hg in group M and C respectively. The difference was non- significant (P> 0.05). Before premedication and 90 minutes after premedication, Ramsay Sedation score in group M was 2.0 and 3.3 respectively and in group C was 1.97 and 2.1 respectively. The difference was significant (P< 0.05). Before premedication and 90 minutes after premedication, Stanford sleepiness scale in group M was 1.37 and 4.57 respectively and in group C was 1.03 and 1.40 respectively. The difference was significant (P< 0.05). Conclusion: Compared to placebo, oral melatonin provides increased sedation and sleepiness while maintaining greater hemodynamic stability during endotracheal intubation. However, when used alone for anxiolysis, melatonin appears to be comparable to placebo. Further research is necessary to establish the optimal and safe dosage of oral melatonin for achieving anxiolytic effects in cancer patients.